fda semaglutide warning news october 2025 Wegovy® Lawsuit FDA Approvals in Cardiometabolic Health:

CrossRef Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition Nitin A

The FDA signaled escalating enforcement, and on April 30, 2026, it proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulks list - the mechanism that governs which substances large-scale compounders may use - with a public comment period open through June 29, 2026

Several medications use similar eligibility guidelines for chronic weight management

The resulting bioavailability of oral semaglutide is approximately 1% meaning for every 14 mg tablet of oral Wegovy, roughly 0.14 mg reaches systemic circulation

At 1 mg/mL, anything above 1 mg requires more than a single U-100 syringe can hold

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape